Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up
2022; Elsevier BV; Volume: 140; Issue: Supplement 1 Linguagem: Inglês
10.1182/blood-2022-159169
ISSN1528-0020
AutoresNiels WCJ van de Donk, Mounzer Agha, Adam D. Cohen, Yaël Cohen, Sébastien Anguille, Tessa Kerre, Wilfried Roeloffzen, Jordan M. Schecter, Kevin C. De Braganca, Carolyn C. Jackson, Helen Varsos, Pankaj Mistry, Tito Roccia, Xiaoying Xu, Katherine Li, Enrique Zudaire, Christina Corsale, Muhammad Akram, Dong Geng, Lida Pacaud, Pieter Sonneveld, Sonja Zweegman,
Tópico(s)CAR-T cell therapy research
Referência(s)